1. Home
  2. Downgrades
  3. Analyst Finds It Difficult To Make Numeric Assumptions For Chemours: Here’s Why

Analyst Finds It Difficult To Make Numeric Assumptions For Chemours: Here’s Why

6
0

BMO Capital Markets analyst John P. McNulty downgraded The Chemours Company (NYSE:CC) to Underperform from Outperform at a lowered price target of $19 (from $45).

The analyst re-rated the stock after the company disclosed management changes and further delay in filing its 10-K.

This week, the company said it is delaying its fourth quarter results and 10-K, which was previously expected on February 28 and February 29, 2024, respectively. 

RelatedChemours Stock Tumbles As …

Full story available on Benzinga.com

Visited 6 times, 1 visit(s) today